---
title: "Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: Dosing and administration questions"
description: "Dosing and administration questions on Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing, Treatment combinations, and Treatment duration. Questions: What is the Imbruvica dose for CLL/SLL? What is the maximum dose of Imbruvica? How many mL of Imbruvica oral suspension is a 420 mg dose? Should Imbruvica be taken before rituximab or obinutuzumab on infusion days? 3 further questions follow. 7 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: Dosing and administration questions

Manufacturer: Pharmacyclics LLC; Janssen Biotech, Inc.  
Prescribing information: [Imbruvica](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf)

Dosing and administration questions that apply to every indication of Imbruvica are on [Imbruvica (ibrutinib), all indications: Dosing and administration](https://www.evicenter.com/medical-information/imbruvica/dosing-and-administration).

## Dosing

<a id="imbruvica-cll-dose"></a>

### What is the Imbruvica dose for CLL/SLL?

> “The recommended dosage of IMBRUVICA for CLL/SLL and WM is 420 mg orally once daily 
> until disease progression or unacceptable toxicity.  
> For CLL/SLL, IMBRUVICA can be administered as a single agent, in combination with 
> rituximab or obinutuzumab, or in combination with bendamustine and rituximab (BR).”

Source: [IMBRUVICA: Prescribing information, page 2, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=2)

> “MONOTHERAPY
> 420 mg
> once daily
> IN COMBINATION
>
> + rituximab, obinutuzumab, or BR*
>
> 420 mg
> once daily
>
> Continue IMBRUVICA<sup>®</sup> treatment until disease progression or unacceptable toxicity.<sup>1</sup>”

Source: [IMBRUVICA: Dosing & Administration - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-and-administration#:~:text=MONOTHERAPY-,420%20mg,until%20disease%20progression%20or%20unacceptable)

<a id="imbruvica-max-dose"></a>

### What is the maximum dose of Imbruvica?

> “The recommended dosage of IMBRUVICA for CLL/SLL and WM is 420 mg orally once daily 
> until disease progression or unacceptable toxicity.”

Source: [IMBRUVICA: Prescribing information, page 2, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=2)

> “Ibrutinib exposure increases with doses up to 840 mg (2 times the maximum approved 
> recommended dosage) in patients with B-cell malignancies.”

Source: [IMBRUVICA: Prescribing information, page 35, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=35)

> “At a single dose 4 times the maximum recommended dose (1680 mg), IMBRUVICA did not 
> prolong the QT interval to any clinically relevant extent.”

Source: [IMBRUVICA: Prescribing information, page 34, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=34)

Note: The Prescribing Information describes 840 mg as 2 times the maximum approved recommended dosage and 1680 mg as 4 times the maximum recommended dose; both correspond to the recommended dosage of 420 mg once daily.

<a id="imbruvica-oral-suspension-dose"></a>

### How many mL of Imbruvica oral suspension is a 420 mg dose?

> “START AT APPROVED DOSE 420 mg (6 mL)”

Source: [IMBRUVICA: Dosing Side-by-Side Flashcard, page 3, captured 2026-11-13](https://www.imbruvicahcp.com/CLL-RESONATE-2-Brochure.pdf#page=3)

> “Each mL contains 70 mg of ibrutinib.”

Source: [IMBRUVICA: Prescribing information, page 53, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=53)

Note: The 6 mL volume is from the dose modifications table of the RESONATE-2 brochure that the dosing page links; the concentration is from the How Supplied section of the Prescribing Information.

<a id="imbruvica-dose-reduction-noncardiac"></a>

### How is the Imbruvica dose reduced for non-cardiac side effects?

> “For adverse reactions listed in Table 2, interrupt IMBRUVICA therapy. Once the adverse 
> reaction has improved to Grade 1 or baseline (recovery), follow the recommended dosage 
> modifications (see Table 2).”

Source: [IMBRUVICA: Prescribing information, page 3, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=3)

> “Other Grade 3 or 4 non-
> hematological toxicities<sup>d</sup> 
> Grade 3 or 4 neutropenia 
> with infection or fever 
> Grade 4 hematological 
> toxicities 
> First 
> Restart at 280 mg daily”

Source: [IMBRUVICA: Prescribing information, page 4, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=4)

> “Second 
> Restart at 140 mg daily”

Source: [IMBRUVICA: Prescribing information, page 4, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=4)

> “Third 
> Discontinue IMBRUVICA”

Source: [IMBRUVICA: Prescribing information, page 4, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=4)

> “<sup>b</sup> Grading based on National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria, or 
> International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for hematologic toxicities in CLL/SLL.”

Source: [IMBRUVICA: Prescribing information, page 4, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=4)

> “<sup>d</sup> For Grade 4 non-hematologic toxicities, evaluate the benefit-risk before resuming treatment.”

Source: [IMBRUVICA: Prescribing information, page 4, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=4)

Note: The spans are the rows of Table 2 for the starting dose of 420 mg, which applies to CLL/SLL.

<a id="imbruvica-dose-reduction-cardiac"></a>

### How is Imbruvica adjusted for heart failure or arrhythmias?

> “Grade 2 cardiac failure 
> First 
> Restart at 280 mg daily<sup>c</sup>”

Source: [IMBRUVICA: Prescribing information, page 4, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=4)

> “Second 
> Restart at 140 mg daily<sup>c</sup>”

Source: [IMBRUVICA: Prescribing information, page 4, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=4)

> “Third 
> Discontinue IMBRUVICA”

Source: [IMBRUVICA: Prescribing information, page 4, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=4)

> “Grade 3 cardiac arrhythmias 
> First 
> Restart at 280 mg daily<sup>c</sup>”

Source: [IMBRUVICA: Prescribing information, page 4, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=4)

> “Second 
> Discontinue IMBRUVICA”

Source: [IMBRUVICA: Prescribing information, page 4, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=4)

> “Grade 3 or 4 cardiac failure  
> Grade 4 cardiac arrhythmias  
> First 
> Discontinue IMBRUVICA”

Source: [IMBRUVICA: Prescribing information, page 4, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=4)

> “<sup>c</sup> Evaluate the benefit-risk before resuming treatment.”

Source: [IMBRUVICA: Prescribing information, page 4, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=4)

Note: The label spans are the rows of Table 2 for the starting dose of 420 mg, which applies to CLL/SLL.

## Treatment combinations

<a id="imbruvica-combination-timing"></a>

### Should Imbruvica be taken before rituximab or obinutuzumab on infusion days?

> “Agents administered in combination with IMBRUVICA<sup>®</sup> require infusion. When administering IMBRUVICA<sup>®</sup> in combination with rituximab or obinutuzumab, consider administering IMBRUVICA<sup>®</sup> prior to rituximab or obinutuzumab when given on the same day.”

Source: [IMBRUVICA: Dosing & Administration - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-and-administration#:~:text=Agents%20administered%20in%20combination%20with,given%20on%20the%20same%20day.)

## Treatment duration

<a id="imbruvica-treatment-duration"></a>

### How long do patients stay on Imbruvica for CLL (RESONATE-2)?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “Continue IMBRUVICA<sup>®</sup> treatment until disease progression or unacceptable toxicity.<sup>1</sup>”

Source: [IMBRUVICA: Dosing & Administration - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-and-administration#:~:text=once%20daily-,Continue,until%20disease%20progression%20or%20unacceptable)

> “The median duration of IMBRUVICA<sup>®</sup> treatment was 74 months (range, 0.7-96.6 months; n=135)<sup>7</sup>”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=MONTHS-,The%20median%20duration%20of,74%20months%20%28range%2C%200.7%2D96.6%20months%3B)

> “These data are descriptive in nature only and have no implications regarding efficacy or safety”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=These%20data%20are%20descriptive%20in,implications%20regarding%20efficacy%20or%20safety)

Note: The 74-month median is from the up to 8-year follow-up of RESONATE-2, which the dose modifications page cites (Barr et al., Blood Adv 2022) and which is not included in the Prescribing Information.

## Related pages
- [Medical information: Imbruvica (ibrutinib): Chronic lymphocytic leukemia and small lymphocytic lymphoma](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma)
- [Indication](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/safety)
- [Specific populations](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/drug-interactions)
- [Access and coverage](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/guidelines)
